Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer Read More Apr 20, 2023
Abdera skyrockets out of stealth with $142M as radiopharmaceutical ambitions take flight Read More Apr 20, 2023
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement Read More Feb 27, 2023
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer Read More Feb 27, 2023
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares Read More Feb 26, 2023
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting Read More Feb 24, 2023
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity Read More Feb 22, 2023
